Combined Acetylcholinesterase Inhibitor and Quaternary Ammonium Antimuscarinic Therapy to Alter Progression of Cognitive Diseases
OwnerSteven A. Richinventor
Life of this patent
Estimating the term…
Abstract
A method administers quaternary ammonium anti-cholinergic muscarinic receptor antagonists in combination with acetyl-cholinesterase inhibitors to treat either cognitive impairment or acute delirium. This therapy results in a modification of a cognitive disorder or disease, namely a slow down in the disease progression. In one preferred embodiment, the disease is dementia with Lewy Bodies. New formulations for quaternary ammonium anti-cholinergic muscarinic receptor antagonists are also disclosed.
Claims23
A method for altering a disease progression of a cognitive disorder comprising the step of administering to the patient a therapeutic amount of a quaternary ammonium anti-cholinergic muscarinic receptor antagonist and a therapeutic amount of an acetyl-cholinesterase inhibitor.
In human patients suffering from dementia with Lewy Bodies, a method for improving cognitive function comprising administering to the patient a therapeutic amount of the combination of rivastigmine and glycopyrrolate.
A quaternary ammonium anti-cholinergic muscarinic receptor antagonist comprising a salt comprising a lipophilic anion as an anionic component of the salt.
Dependencies are inferred from the claim text.